NITRONOR

Dosage

Children: Paediatric fluid requirements should be calculated based on age, weight, and clinical condition. Refer to the guidelines in the BNF for Children for detailed recommendations.

Adults: Dosage in litres may vary depending on clinical circumstances, such as fluid resuscitation needs, maintenance fluid requirements, or medication delivery. Refer to clinical guidelines for specific scenarios.

Mechanism of action

Litres do not have a pharmacological mechanism of action as they are a unit of measurement rather than a drug. However, the administration of fluids measured in litres can influence various physiological processes, including hydration status, electrolyte balance, and overall fluid homeostasis in the body.

Pharmacodynamics

As a measurement unit, litres do not exhibit pharmacodynamics. However, the volume of fluid administered can impact the pharmacodynamics of medications that are diluted or delivered in fluid form, affecting the rate of absorption, distribution, metabolism, and excretion of drugs.

Pharmacokinetics

Litres as a unit of volume do not possess pharmacokinetic properties. The pharmacokinetics of a drug may be influenced by the volume of fluid in which it is administered, as this can affect the concentration of the drug in the bloodstream and its subsequent pharmacological effects.

Indications

• Used as a solubilizing agent in pharmaceutical preparations
• Used in radiographic contrast media formulations

Dosage

Children: Refer to specific formulations for paediatric dosing instructions as it varies depending on the application.

Adults: Refer to specific formulations for adult dosing instructions as it varies depending on the application.

Mechanism of action

Meglumine acts by enhancing the solubility and stability of drugs in solution, particularly in radiographic contrast agents. It is involved in purinergic signaling pathways, which are essential for various physiological processes, including neurotransmission and inflammation.

Pharmacodynamics

The pharmacodynamic profile of meglumine is largely influenced by its role as a solubilizing agent. It does not exhibit direct pharmacological effects on its own but rather facilitates the action of other active ingredients in formulations. Its impact on purinergic signaling may contribute to modulating physiological responses in the body.

Pharmacokinetics

Meglumine is rapidly absorbed when administered, with its pharmacokinetics closely tied to the properties of the drugs it accompanies. The distribution, metabolism, and excretion of meglumine are not well-defined as it typically functions as an excipient rather than an active therapeutic agent. Its elimination from the body is primarily via renal pathways.

Pregnancy

There is insufficient data on the use of meglumine in pregnancy, therefore it should only be used if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised when administering meglumine to breastfeeding women, as its effects on infants are not well studied.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Fascioliasis
• Liver fluke infections
• Other helminth infections in livestock

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations.

Adults: Refer to the BNF for specific dosing guidelines.

Mechanism of action

Nitroxynil disrupts the energy metabolism of helminths by interfering with mitochondrial function, leading to depletion of ATP levels. This results in paralysis and death of the parasites, making it effective against certain types of flukes and other parasitic infections.

Pharmacodynamics

The pharmacodynamics of nitroxynil involves its action as a potent inhibitor of oxidative phosphorylation in the mitochondria of parasites. The drug is selectively toxic to helminths, making it safe for use in animals when administered in appropriate doses. Its effects typically manifest through rapid paralysis and destruction of the parasites.

Pharmacokinetics

Nitroxynil is absorbed following administration and is metabolized primarily in the liver. It has a moderate half-life, allowing for effective dosing intervals. The drug's elimination occurs mainly through urine and feces, with metabolites also being excreted. Bioavailability may vary based on the route of administration.

Adverse effects

• Skin irritation
• Nausea
• Vomiting
• Anorexia
• Diarrhea

Precautions

• Use with caution in patients with a history of hypersensitivity to nitroxynil or similar compounds.
• Monitor liver function during treatment, especially in patients with pre-existing liver conditions.

Pregnancy

Nitroxynil should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. There is limited data on its safety in pregnant women.

Breast-feeding

It is not known if nitroxynil is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Injectable solution